Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)

Trial Details

NCT ID
NCT06250036
Phase
PHASE2
Sponsor
Royal Marsden NHS Foundation Trust
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • Single agent zimberelimab
  • Combination zimberelimab + domvanalimab
Locations (sample)
  • Cambridge, Cambridgeshire, United Kingdom|52.2,0.11667
  • Exeter, Devon, United Kingdom|50.7236,-3.52751
  • Dundee, Dundee, United Kingdom|56.46913,-2.97489
  • Canterbury, Kent, United Kingdom|51.27904,1.07992
  • London, London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Age: ≥18 years
  • Histologically confirmed gastric or gastro-oesophageal junctional (GOJ) adenocarcinoma (inclusive of Siewert-stein classification type I-III (62))
  • MMRd/MSI-H. There are three different methods validated for detection (63) :
  • Immunohistochemistry (IHC) staining for expression of MMR proteins (MLH1, MSH2, PMS2 and MSH6), MMRd defined as loss of function or one or more of …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →